P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

Bibliographic Details
Main Authors:	Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim Linton, Pam Mckay, Sophie Leitch, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Peter Browett, Catherine Thieblemont, Anna Marina Liberati, Emmanuel Bachy, Federica Cavallo, Régis Costello, Sunil Iyengar, Roberto Marasca, Heidi Mociková, Jin Seok Kim, Dipti Talaulikar, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971232.77003.b0

Similar Items

P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)
by: Catherine Thieblemont, et al.
Published: (2023-08-01)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
by: S. Opat, et al.
Published: (2022-06-01)

P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)
by: Catherine Thieblemont, et al.
Published: (2023-08-01)

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents
by: Chiara Tarantelli, et al.
Published: (2019-07-01)

P687: A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 AS MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH B-CELL MALIGNANCIES: PRELIMINARY DATA
by: S. Opat, et al.
Published: (2022-06-01)

Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia
by: Rhodes JM, et al.
Published: (2021-03-01)

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia
by: Jad Othman, et al.
Published: (2018-05-01)

P609: EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.
by: Maria Andersson, et al.
Published: (2023-08-01)

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)
by: M. Dimopoulos, et al.
Published: (2022-06-01)

Zanubrutinib: past, present, and future
by: Constantine S. Tam, et al.
Published: (2023-09-01)

Correction: Zanubrutinib: past, present, and future
by: Constantine S. Tam, et al.
Published: (2023-10-01)

P639: ZANUBRUTINIB (ZANU) VS BENDAMUSTINE + RITUXIMAB (BR) IN PATIENTS (PTS) WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EXTENDED FOLLOW-UP OF THE SEQUOIA STUDY
by: Talha Munir, et al.
Published: (2023-08-01)

P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN TRIAL LONG-TERM FOLLOW-UP
by: Alessandra Tedeschi, et al.
Published: (2023-08-01)

Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL)
by: Matteo Scortichini, et al.
Published: (2025-03-01)

Efficacy of Zanubrutinib in the Treatment of Bing–Neel Syndrome
by: Jonathan Wong, et al.
Published: (2018-12-01)

P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL
by: P. Strati, et al.
Published: (2022-06-01)

Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC)
by: Pei-Wen Yang, et al.
Published: (2019-11-01)

S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL
by: P. L. Zinzani, et al.
Published: (2022-06-01)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
by: Hongzhi Geng, et al.
Published: (2023-08-01)

Nationalists with no nation: oral history, ZANU(PF) and the meanings of Rhodesian student activism in Zimbabwe
by: Hodgkinson, D
Published: (2019)

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
by: Constantine Tam, et al.
Published: (2023-04-01)

FUNCTIONAL IMPLICATIONS OF THE CLOCK 3111T/C SINGLE-NUCLEOTIDE POLYMORPHISM
by: Angela Renee Ozburn, et al.
Published: (2016-04-01)

Transnationalism, contingency and loyalty in African Liberation Armies: The case of ZANU’s 1974–75 Nhari Mutiny
by: Tendi, B
Published: (2017)

Regulation of Glioma Cell Migration by Seri ne-Phosphorylated P3111
by: Wendy S. McDonough, et al.
Published: (2005-09-01)

P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL
by: M. Tatarczuch, et al.
Published: (2022-06-01)

مدينة طلبيرة الأندلسية Talavera 94-477هـ / 712-1084م
by: Jassim Al-Darwish, et al.
Published: (2021-08-01)

La modernización del derecho alemán de obligaciones: la reforma del BGB
by: Albert Lamarca i Marquès
Published: (2008-02-01)

La modernització del dret alemany d'obligacions: la reforma del BGB
by: Albert Lamarca i Marquès
Published: (2008-02-01)

Отримання та характеристика продуктів деструкції пептидоглікану Lactobacillus acidophilus K 3111
by: A.I. Kapustian, et al.
Published: (2018-03-01)

Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study
by: Natalie S. Grover, et al.
Published: (2024-10-01)

1084 A double-inversion radial FSE and GRASE methods for the evaluation of cardiac masses
by: Sorrell Vincent, et al.
Published: (2008-10-01)

PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
by: Antonio Salar Silvestre, et al.
Published: (2023-08-01)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
by: Judith Trotman, et al.
Published: (2023-08-01)

Sistemas BGB y BSC (1949-56). Las viviendas prefabricadas de Antonio Bonet
by: Salud María Torres-Dorado, et al.
Published: (2019-04-01)

Polymorphism T3111C of the Clock gene in ethnic groups of women from Russia and Buryatia
by: O. V. Kaluzhnaya, et al.
Published: (2018-04-01)

Study of the association between 3111T/C polymorphism of the CLOCK gene and the presence of overweight in schoolchildren
by: Nayara P. Giovaninni, et al.
Published: (2014-09-01)

Study of the association between 3111T/C polymorphism of the CLOCK gene and the presence of overweight in schoolchildren,
by: Nayara P. Giovaninni, et al.
Published: (2014-09-01)

Study of the association between 3111T/C polymorphism of the CLOCK gene and the presence of overweight in schoolchildren
by: Nayara P. Giovaninni, et al.
Published: (2014-09-01)

Zanubrutinib in lymphoproliferative disorders: a comprehensive review
by: Javier Muñoz, et al.
Published: (2022-05-01)

La politica autoritaria della ZANU-PF in Zimbabwe. La rielaborazione del nazionalismo mediante una “storia patriottica”
by: Mario Zamponi
Published: (2020-12-01)